In 1984, the Lipid Research Clinics Program trial provided modest, if controversial, evidence that cholestyramine was associated with a reduction in the risk of coronary heart disease (CHD) in a primary prevention study of men.1 Other evidence for the emergence of a new treatable risk factor came from epidemiological studies, animal studies, and family studies.2 The National Heart, Lung, and Blood Institute (NHLBI) convened the National Cholesterol Education Program (NCEP) to develop recommendations about the detection, evaluation, and treatment of cholesterol in adults. The first Adult Treatment Panel (ATP) used levels of low-density lipoprotein (LDL) cholesterol to define both the thresholds for initiating treatment and the goals or targets of therapy.2
Psaty BM, Weiss NS. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol: A Fresh Interpretation of Old Evidence. JAMA. 2014;311(5):461–462. doi:10.1001/jama.2013.284203
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.